Why inflammatory back pain is easy to miss
Low back pain is common, but a small subset is driven by immune inflammation rather than strain, disc disease, or age related degeneration. That distinction matters because axial spondyloarthritis, including ankylosing spondylitis when sacroiliac or spinal damage is visible on imaging, often begins before age forty and may smolder for years before diagnosis. For patients, delayed recognition means preventable stiffness, fatigue, sleep disruption, and loss of function. For primary care clinicians, the challenge is deciding which back pain pattern deserves a rheumatologic workup.
The 2022 Assessment of SpondyloArthritis international Society and EULAR recommendations, and the 2019 American College of Rheumatology, Spondylitis Association of America, and SPARTAN treatment guideline, emphasize a structured approach: recognize inflammatory features, confirm objective evidence of inflammation when possible, and match therapy to disease activity, comorbidity, and patient goals.
The pattern that should raise suspicion
Inflammatory back pain is a clinical pattern, not a diagnosis by itself. The classic history includes pain lasting at least three months, onset before age forty five, gradual rather than sudden onset, improvement with exercise, poor improvement with rest, and prominent morning stiffness or second half of the night pain. Many patients describe feeling older than their age when getting out of bed, then loosening as the day starts.
What separates axial spondyloarthritis from ordinary back pain
Mechanical back pain often follows lifting, twisting, prolonged sitting, osteoarthritis, or disc pathology. It may improve with rest and fluctuate with posture. Axial spondyloarthritis is different because enthesitis, inflammation where ligaments and tendons attach to bone, affects the sacroiliac joints and spine. Over time, some patients develop new bone formation and fusion, which is why ankylosing spondylitis literally means an inflamed spine that can become stiffened.
Clues beyond the spine
The spine history is stronger when extra articular clues are present. Alternating buttock pain, heel pain from Achilles or plantar fascia enthesitis, dactylitis, psoriasis, inflammatory bowel disease, and recurrent anterior uveitis all increase the probability. Family history also matters, particularly in first degree relatives with spondyloarthritis, psoriasis, bowel inflammation, or uveitis.
Consider a thirty two year old teacher with eight months of deep buttock and low back pain. She wakes at four in the morning, improves after a shower and walking the dog, and feels worse after a weekend car trip. Her lumbar X ray is normal. That normal film should not end the evaluation; early axial spondyloarthritis can be non radiographic, meaning inflammation is present before structural damage appears on plain radiographs.
Testing is useful, but context comes first
No single blood test rules ankylosing spondylitis in or out. HLA B27 is a genetic marker associated with axial spondyloarthritis, but it is also present in healthy people, and many affected patients are HLA B27 negative. C reactive protein and erythrocyte sedimentation rate can support active inflammation, yet normal results are common. The diagnosis rests on the whole pattern.
A common misconception is that normal imaging excludes disease. In reality, MRI interpretation depends on protocol, reader experience, age, athletic stress, childbirth history, and the pretest probability created by the history. False positives and false negatives both occur, so imaging should answer a focused clinical question, not replace clinical reasoning.
Treatment logic: suppress inflammation, preserve function
Initial management usually includes education, smoking cessation when relevant, and regular exercise with emphasis on spinal mobility, posture, hip extension, and cardiopulmonary conditioning. Nonsteroidal anti inflammatory drugs remain first line pharmacologic therapy in ACR and ASAS EULAR guidance because they reduce pain and stiffness quickly in many patients. The decision to use them continuously or as needed depends on symptom burden, cardiovascular risk, kidney function, gastrointestinal risk, and patient preference.
When disease activity remains high despite an adequate anti inflammatory drug trial, biologic disease modifying therapy is considered. Tumor necrosis factor inhibitors and interleukin 17 inhibitors have strong evidence for axial disease. The ACR guideline generally favors TNF inhibitors as the first biologic class in many situations, while IL 17 blockade is particularly relevant when psoriasis is prominent or when TNF inhibitors are unsuitable. Janus kinase inhibitors have also entered the treatment landscape for active ankylosing spondylitis in selected adults, adding an oral option with distinct safety monitoring.
Why rheumatologists measure response
Treatment is not judged by a single pain score. Rheumatologists track morning stiffness, night pain, function, patient global assessment, inflammatory markers when informative, medication tolerability, and sometimes validated tools such as BASDAI, the Bath Ankylosing Spondylitis Disease Activity Index, or ASDAS, the Ankylosing Spondylitis Disease Activity Score. The point is treat to target thinking: if inflammation is controlled, function should improve and structural risk may fall.
Where the evidence leaves us
Inflammatory back pain is not rare enough to ignore and not common enough to diagnose casually. The evidence supports early recognition, objective assessment, exercise, rational anti inflammatory drug use, and escalation to targeted therapy when active axial spondyloarthritis persists. Uncertainty remains around biomarkers, MRI thresholds, and which advanced therapy should come first for specific phenotypes. The best care still begins with a careful history that notices when back pain behaves like inflammation rather than strain.
Medically reviewed by Dr. Adam Elisha, DO, board-certified rheumatologist in Duluth, MN.